The concomitance of IBD with LS with a specific PMS2 mutation confers to this syndrome, which is normally much more indolent within the Lynch spectrum, with oncological risks more similar to those observed for more aggressive and penetrating genotypes (e.g., MLH1, MSH2). Here, MLH1 is linked to inflammatory bowel disease.